Brokerage Firm Rating on Exelixis (EXEL)

Exelixis (EXEL) : The consensus on Exelixis (EXEL) based on 5 analyst recommendation on the company stock is 1.4, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Exelixis (EXEL) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $12 and the lowest price target forecast is $5. The average forecast of all the analysts is $9.67 and the expected standard deviation is $4.04.


For the current week, the company shares have a recommendation consensus of Buy. Exelixis (NASDAQ:EXEL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.43 and $10.31 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.80. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.66, notching a gain of 2.80% for the day. The total traded volume was 3,461,069 . The stock had closed at $10.37 on the previous day.

In a related news,The officer (Pres Prod Dev & Med Aff & CMO) of Exelixis, Inc., Schwab Gisela sold 42,338 shares at $11 on August 4, 2016. The Insider selling transaction had a total value worth of $465,718. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.